Incyte and TG Therapeutics are two fast-growing pharmaceutical stocks attracting investor attention. Incyte reported first-quarter revenue of $1.27 billion, up 21% year over year, driven by Jakafi sales of $758 million and Opzelura sales of $143 million, with adjusted earnings per share of $1.81 beating analyst estimates. The company anticipates four new approvals and launches through early 2027, supported by a pipeline that includes a recent $1.25 billion acquisition of Vega Therapeutics. TG Therapeutics raised its full-year revenue guidance to $925 million after Briumvi generated $194.8 million in first-quarter U.S. sales, and its strong gross margins and growth make it a potential acquisition target for large pharmaceutical companies.
Incyte CorporationQ1 revenue and earnings beat estimates, plus $1.25B acquisition and pipeline progress
TG Therapeutics IncRaised full-year revenue guidance after strong Briumvi sales, potential acquisition target
Biogen Inc
Novartis AG
Sanofi SA